IP Rights of Novel Psychedelic Compounds Bought by COMPASS Pathways

The mental health care firm COMPASS Pathways plc is ready to acquire patent rights to the application of novel psychedelic-based drugs and medicine.

A wide variety of psychedelics and empathogens (psychoactive drugs that encourage compassion) are on the list. The Intellectual Property portfolio also includes prodrugs (inactive compounds which become an active drug on consumption). Dr. Matthias Grill, Founder and CEO of MiHKAL GmbH in Basel, Switzerland, will be working intensively with COMPASS on this project.

Objectives of the Project

The idea behind the initiative is to produce psychoactive-based drugs which rank high in therapeutic value while meeting the standards of safety. According to Dr. Matthias Grill, the project intends to create novel compounds which will help overcoming today’s mental health issues.

Lars Wilde, President and CEO of Compass Pathways, added that clinical developments will commence within the next 2 years. This will help the collaborative effort to heal people suffering from disorders like depression and PTSD (Post-Traumatic Stress Disorder).